Iovance Biotherapeutics

Iovance Biotherapeutics to Present at Upcoming Conferences

Retrieved on: 
Friday, March 1, 2024

SAN CARLOS, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences:

Key Points: 
  • SAN CARLOS, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences:

Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024

Retrieved on: 
Thursday, February 22, 2024

SAN CARLOS, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full-year 2023 financial results on Wednesday, February 28, 2024.

Key Points: 
  • SAN CARLOS, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full-year 2023 financial results on Wednesday, February 28, 2024.
  • Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m.
  • To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/6gd5c9ve .
  • The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com.

Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024

Retrieved on: 
Friday, February 16, 2024

To participate in the conference call Q&A and live audio webcast, please register at https://register.vevent.com/register/BI0633b8a73e8b4c578bfed2a8ef37003e.

Key Points: 

IN8bio Appoints Dr. Corinne Epperly to Board of Directors

Retrieved on: 
Thursday, December 7, 2023

With over two decades of experience in oncology as a physician and a scientist, Dr. Epperly uniquely combines her medical expertise with business and financial acumen.

Key Points: 
  • With over two decades of experience in oncology as a physician and a scientist, Dr. Epperly uniquely combines her medical expertise with business and financial acumen.
  • “I am thrilled to be joining IN8bio’s Board of Directors and contributing to our shared commitment to advance innovative therapies that can positively impact the lives of cancer patients,” said Corinne Epperly, MD, MPH.
  • Previously she served on the board of AVEO Oncology until its acquisition by LG Chem in early 2023.
  • Dr. Epperly holds a Distinguished Bachelor of Arts in Biochemistry and Biology from the University of Virginia.

BioMarin Announces Governance Enhancements and Value Creation Initiatives

Retrieved on: 
Wednesday, December 20, 2023

SAN RAFAEL, Calif., Dec. 20, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder value creation.

Key Points: 
  • SAN RAFAEL, Calif., Dec. 20, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder value creation.
  • "Today's announcements will strengthen our ability to drive better outcomes for patients with genetic diseases and deliver value to all stakeholders.
  • BioMarin plays a pivotal role in the treatment of genetic diseases thanks to its globally leading rare-disease portfolio.
  • We believe the changes announced today put BioMarin in the best position to realize its full potential, and we support Alexander Hardy as the right leader for this chapter of BioMarin's value creation story.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Friday, November 17, 2023

SAN CARLOS, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on November 16, 2023 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 59,950 shares of Iovance’s common stock to nine new non-executive employees.

Key Points: 
  • SAN CARLOS, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on November 16, 2023 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 59,950 shares of Iovance’s common stock to nine new non-executive employees.
  • The awards were granted under Iovance’s 2021 Inducement Plan, which was adopted on September 22, 2021 and amended on January 12, 2022 and May 10, 2023, and provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each of the stock options granted as referenced in this press release has an exercise price of $4.40, the closing price of Iovance’s common stock on the Date of Grant.
  • Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date (referred to as the “First Vesting Date”), and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the First Vesting Date, subject to continued employment with the Company through the applicable vesting dates.

Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023

Retrieved on: 
Tuesday, October 31, 2023

Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m.

Key Points: 

Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023

As of the data cutoff date of June 16, 2023, median C-144-01 trial follow-up was 48.1 months in heavily pretreated patients with advanced melanoma.

Key Points: 
  • As of the data cutoff date of June 16, 2023, median C-144-01 trial follow-up was 48.1 months in heavily pretreated patients with advanced melanoma.
  • One-time lifileucel TIL therapy demonstrated durable efficacy with a four-year OS rate of 22.2%.
  • Treatment-emergent adverse events were consistent with known safety profiles of lymphodepletion and IL-2, and their incidence decreased over time.
  • Long-term efficacy and safety of lifileucel tumor infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Friday, October 20, 2023

SAN CARLOS, Calif., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on October 20, 2023 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 48,300 shares of Iovance’s common stock to ten new non-executive employees.

Key Points: 
  • SAN CARLOS, Calif., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on October 20, 2023 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 48,300 shares of Iovance’s common stock to ten new non-executive employees.
  • The awards were granted under Iovance’s 2021 Inducement Plan, which was adopted on September 22, 2021 and amended on January 12, 2022 and May 10, 2023, and provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each of the stock options granted as referenced in this press release has an exercise price of $3.33, the closing price of Iovance’s common stock on the Date of Grant.
  • Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date (referred to as the “First Vesting Date”), and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the First Vesting Date, subject to continued employment with the Company through the applicable vesting dates.

Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress

Retrieved on: 
Monday, October 16, 2023

The abstract reports outcomes of a subset of 12 patients with advanced mucosal melanoma treated with lifileucel in the pooled consecutive cohorts from the C-144-01 trial.

Key Points: 
  • The abstract reports outcomes of a subset of 12 patients with advanced mucosal melanoma treated with lifileucel in the pooled consecutive cohorts from the C-144-01 trial.
  • Patients with mucosal melanoma, which is rare and difficult to treat, have worse outcomes after anti–PD-1 therapy compared to patients with other melanoma subtypes.
  • The ORR assessed by an independent review committee (IRC) using RECIST v1.1 was 50% (95% CI: 21%–79%).
  • Treatment emergent adverse events (TEAEs) were consistent with known safety profiles of lymphodepleting chemotherapy and interleukin-2 (IL-2).